One year after FDA’s rejection of Lykos Therapeutics’ MDMA-assisted therapy for PTSD application, insiders and observers reflect on what went wrong and what comes next. This in-depth, interview-led coverage explores the decisive factors behind the CRL, lessons learned, and the future of psychedelic drug development.| Psychedelic Alpha
In part 2 of our series on campaign finance, new complaints filed by former staffers of the Massachusetts Yes on 4 psychedelics initiative to the Massachusetts Office of Campaign and Political Finance appear to contradict assertions from a senior campaign advisor that payments were done in accordance with state law. The post Details of Alleged MA Initiative Campaign Finance Violations In New OCPF Complaints first appeared on Lucid News. The post Details of Alleged MA Initiative Campaign Finan...| Lucid News
Germany has become the first EU country to allow legal access to psilocybin under a compassionate use program for treatment-resistant depression. Unlike other countries’ pre-approval pathways, Germany’…| Psychedelic Alpha